文献速递妇科生殖医学

21-羟化酶缺陷所致非经典型先天性肾上腺增生再审视:以青少年和成年女性为重点的更新

Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.
PubMed 文献 · Hum Reprod Update · 2017-01-01

本文系统综述了21-羟化酶缺陷所致非经典型先天性肾上腺增生(NCAH)的流行病学、病理生理、诊断和治疗,并进行了流行病学数据的Meta分析。在雄激素过多症状女性中,全球NCAH患病率为4.2%(95%CI 3.2-5.4%)。诊断依据血清17-羟孕酮(17-OHP)浓度,治疗需个体化。

要点

  • 在雄激素过多症状女性中,NCAH全球患病率为4.2%(95%CI 3.2-5.4%)。
  • 筛查用基础17-OHP≥2 ng/ml(6 nmol/l),确诊需基础或促皮质素刺激后17-OHP≥10 ng/ml(30 nmol/l)。
  • 治疗应个体化,糖皮质激素可用于特定情况,口服避孕药和/或抗雄激素药物控制症状。

核心结论

  • 基于证据的诊断和治疗策略对NCAH女性的规范管理至关重要,尤其应考虑患者随访不同阶段可能需要不同治疗策略,且适当遗传咨询可预防其子女发生经典型CAH。

研究设计与样本

  • 系统综述和批判性评估,检索MEDLINE、EMBASE、Cochrane、ERIC、EBSCO、学位论文摘要和Current Contents等多个数据库,纳入截至2016年10月发表的经同行评议的NCAH研究,并进行了流行病学数据的Meta分析。

主要发现

  • 在雄激素过多症状女性中,NCAH全球患病率为4.2%(95%CI 3.2-5.4%)。
  • NCAH临床后果从婴儿期加速生长,到青春期和成年期 premature pubarche、皮肤症状及类似多囊卵巢综合征(PCOS)的稀发排卵。
  • 诊断依据血清17-OHP浓度,筛查用基础17-OHP≥2 ng/ml(6 nmol/l),确诊需基础或cosyntropin刺激后17-OHP≥10 ng/ml(30 nmol/l)。
  • CYP21A2基因分子遗传学分析可用于确认,并应所有NCAH患者提供遗传咨询,因这些患者常携带可能导致子代经典型CAH的等位基因。
  • NCAH患者流产风险较高,妊娠期可能受益于糖皮质激素治疗。

关键数值与推荐

  • 筛查:基础17-OHP≥2 ng/ml(6 nmol/l),若无可用的更合适本机构cut-off值。
  • 确诊:17-OHP≥10 ng/ml(30 nmol/l),基础或cosyntropin刺激后。
  • 治疗应个体化;糖皮质激素替代治疗可能受益于加速生长或骨龄提前的儿科患者或寻求生育的成年女性;口服避孕药和/或抗雄激素药物最佳控制月经不规则、多毛症和其他皮肤症状;部分女性可能需要诱导排卵或辅助生殖技术;NCAH患者流产风险较高,妊娠期可能受益于糖皮质激素治疗。

临床怎么用

  • 在雄激素过多症状女性中,应使用基础17-OHP≥2 ng/ml(6 nmol/l)进行筛查(若无可用的更合适本机构cut-off值)。
  • 确诊需17-OHP≥10 ng/ml(30 nmol/l),基础或cosyntropin刺激后。
  • CYP21A2基因分子遗传学分析可用于确认,并应所有NCAH患者提供遗传咨询。
  • 治疗必须个体化:糖皮质激素替代治疗可能受益于加速生长或骨龄提前的儿科患者或寻求生育的成年女性;口服避孕药和/或抗雄激素药物最佳控制月经不规则、多毛症和其他皮肤症状。
  • 部分女性可能需要诱导排卵或辅助生殖技术以实现妊娠;NCAH患者流产风险较高,妊娠期可能受益于糖皮质激素治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-classic congenital hyperplasia (NCAH) due to 21-hydroxylase deficiency is a common autosomal recessive disorder characterized by androgen excess. OBJECTIVE AND RATIONALE: We conducted a systematic review and critical assessment of the available evidence pertaining to the epidemiology, pathophysiology, diagnosis and management of NCAH. A meta-analysis of epidemiological data was also performed. SEARCH METHODS: Peer-reviewed studies evaluating NCAH published up to October 2016 were reviewed. Multiple databases were searched including MEDLINE, EMBASE, Cochrane, ERIC, EBSCO, dissertation abstracts, and current contents. OUTCOMES: The worldwide prevalence of NCAH amongst women presenting with signs and symptoms of androgen excess is 4.2% (95% confidence interval: 3.2-5.4%). The clinical consequences of NCAH expand from infancy, i.e. accelerated growth, to adolescence and adulthood, i.e. premature pubarche, cutaneous symptoms and oligo-ovulation in a polycystic ovary syndrome (PCOS)-like clinical picture. The diagnosis of NCAH relies on serum 17-hydroxyprogesterone (17-OHP) concentrations. A basal 17-OHP concentration ≥2 ng/ml (6 nmol/l) should be used for screening if more appropriate in-house cut-off values are not available. Definitive diagnosis requires a 17-OHP concentration ≥10 ng/ml (30 nmol/l), either basally or after cosyntropin-stimulation. Molecular genetic analysis of the CYP21A2 gene, which is responsible for 21-hydroxylase activity, may be used for confirmation purposes and should be offered to all patients with NCAH along with genetic counseling because these patients frequently carry alleles that may result in classic CAH, the more severe form of the disease, in their progeny. Treatment must be individualized. Glucocorticoid replacement therapy may benefit pediatric patients with accelerated growth or advanced bone age or adult women seeking fertility, whereas adequate control of menstrual irregularity, hirsutism and other cutaneous symptoms is best served by the use of oral contraceptive pills and/or anti-androgens. Some women may need ovulation induction or assisted reproductive technology to achieve pregnancy. Patients with NCAH have a higher risk of miscarriage and may benefit from glucocorticoid treatment during pregnancy. WIDER IMPLICATIONS: Evidence-based diagnostic and treatment strategies are essential for the proper management of women with NCAH, especially considering that these patients may need different therapeutic strategies at different stages during their follow-up and that appropriate genetic counseling may prevent the occurrence of CAH in their children.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update. 2017. PMID: 28582566. doi:10.1093/humupd/dmx014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。